From the Department of Neurology (R.B., L.M., E.L., J.D.) and Division of Neurocritical Care (R.B.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Department of Neurology (F.G., J.D.), Hospital Clinic, University of Barcelona/Institut d'Investigacions Biomediques August Pi i Sunyer; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands.
Neurology. 2019 Jan 15;92(3):e244-e252. doi: 10.1212/WNL.0000000000006783. Epub 2018 Dec 21.
To construct a grading score that predicts neurologic function 1 year after diagnosis of anti-NMDA receptor (NMDAR) encephalitis.
Three hundred eighty-two patients with detailed information and functional status at 1 year were studied. Factors associated with poor status (defined as modified Rankin Scale score ≥3) were identified and incorporated into a multivariate logistic regression model. This model was used to develop a 5-point prediction score, termed the anti-NMDAR Encephalitis One-Year Functional Status (NEOS) score.
Intensive care unit admission ( < 0.001), treatment delay >4 weeks ( = 0.012), lack of clinical improvement within 4 weeks ( < 0.001), movement disorder ( = 0.001), central hypoventilation ( < 0.001), elevated CSF white blood cell count ( < 0.001), elevated CSF protein level ( = 0.027), and abnormal MRI ( = 0.002) were associated with 1-year functional status in univariate analysis. Intensive care unit admission, treatment delay >4 weeks, lack of clinical improvement within 4 weeks, abnormal MRI, and CSF white blood cell count >20 cells/μL were independent predictors for outcome in multivariate regression modeling. These 5 variables were assigned 1 point each to create the NEOS score. NEOS score strongly associated with the probability of poor functional status at 1 year (3% for 0 or 1 point to 69% for 4 or 5 points, < 0.001).
The NEOS score accurately predicts 1-year functional status in patients with anti-NMDAR encephalitis. This score could help estimate the clinical course following diagnosis and may aid in identifying patients who could benefit from novel therapies.
构建一种评分系统,预测抗 N-甲基-D-天冬氨酸受体(NMDAR)脑炎患者诊断后 1 年的神经功能。
研究了 382 例详细资料和 1 年时功能状态的患者。确定与不良状态相关的因素(定义为改良 Rankin 量表评分≥3),并将其纳入多变量逻辑回归模型。该模型用于开发 5 分预测评分,称为抗 NMDAR 脑炎 1 年功能状态(NEOS)评分。
重症监护病房收治(<0.001)、治疗延迟>4 周(=0.012)、4 周内无临床改善(<0.001)、运动障碍(=0.001)、中枢性通气不足(<0.001)、脑脊液白细胞计数升高(<0.001)、脑脊液蛋白水平升高(=0.027)和异常 MRI(=0.002)在单因素分析中与 1 年功能状态相关。重症监护病房收治、治疗延迟>4 周、4 周内无临床改善、异常 MRI 和脑脊液白细胞计数>20 个/μL 是多变量回归模型中预后的独立预测因素。这 5 个变量各赋值 1 分,创建 NEOS 评分。NEOS 评分与 1 年时不良功能状态的概率密切相关(0 或 1 分的概率为 3%,4 或 5 分的概率为 69%,<0.001)。
NEOS 评分能准确预测抗 NMDAR 脑炎患者 1 年的功能状态。该评分有助于估计诊断后的临床过程,并可能有助于识别可能从新疗法中受益的患者。